Glenmark gains on final ANDA approval for Eszopiclone - The New Indian Express

Glenmark gains on final ANDA approval for Eszopiclone

Published: 16th April 2014 01:19 PM

Last Updated: 16th April 2014 01:19 PM

Glenmark Pharmaceutical, a manufacturer of generic formulation products and API, gained on Wednesday after its USA a subsidiary, Glenmark Generics Inc. has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Eszopiclone Tablets. Glenmark will commence distribution of the product immediately.

Eszopiclone Tablets are Glenmark's generic version of Sunovion's Lunesta. Eszopiclone is indicated for the treatment of insomnia. The approval is for the 1mg, 2mg and 3mg tablets. Shares ofthe companyare trading at Rs 586, up Rs 4.65, or 0.80% at the Bombay Stock Exchange (BSE) on Wednesday at 12:07 p.m.The scrip has touched an intra-day high of Rs 587 and low of Rs 582.50. The total volume of shares traded at the BSE is 8,887.In the earlier session, the shares climbed 1.23%, or Rs 7.05, at Rs 581.35. Currently, the stock is trading down 4.25% from its 52-week high of Rs 612 and above 25.35% over the 52-week low of Rs 467.50.

comments powered by Disqus

Disclaimer: We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the NIE editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.


Read More



follow us Mobile Site iPad News Hunt Android RSS Tumblr Linekin Pinterest Youtube Google Plus Twitter Facebook